• JULY 24, 2000

Hoechst Marion Roussel: Net up 43% despite lower sales

Hoechst has reported a 47% growth in net profit despite a reduction in the turnover.

  FY00 FY01 change
Sales 1330 1300 -2%
PBT* 116 146 26%
PAT 54 77 43%

The turnover has reduced due to a sale of two of its brands Haemaccel and Omnatax to Nicholas Piramal last year.

At the AGM held on Monday July 24th, the company's Chairman Mr Vijay Mallya, announced that the restructuring that the company had undertaken over three year's ago is almost complete. The company has been introducing new products from the parent's stable such as Amaryl (an anti–diabetic), Allegra (respiratory) and Cardace (cardiovascular). It has plans to introduce Recombinant Insulin and Arava (a musculo–skeletal) in the future.

The Chairman expects the company to grow its topline by 10% plus in the current financial year.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407